HSF1 Pathway Inhibitor Clinical Candidate (CCT361814/NXP800) Developed from a Phenotypic Screen as a Potential Treatment for Refractory Ovarian Cancer and Other Malignancies

Authors: Elisa Pasqua, Swee Y. Sharp, N. Chessum, Angela Hayes, Loredana Pellegrino, Michael Tucker, Asadh Miah, Birgit Wilding, Lindsay E. Evans, Carl S. Rye, N. Yi Mok, Manjuan Liu, Alan T. Henley, Sharon Gowan, Emmanuel de Billy, Robert te Poele, Marissa Powers, Suzanne A. Eccles, Paul A. Clarke, Florence I. Raynaud, Paul Workman, Keith Jones, Matthew D. Cheeseman - Journal of Medicinal Chemistry 2023 cited by 28

has now progressed to phase 1 clinical trial as a potential future treatment for refractory ovarian cancer and other malignancies.